Related by context. All words. (Click for frequent words.) 72 pharmacokinetic 72 tolerability 68 pharmacokinetic profile 68 antiviral activity 67 pharmacokinetics 67 antiviral efficacy 66 efficacy 66 pharmacodynamics 66 antibody responses 66 immune responses 65 reactogenicity 65 pharmacokinetics PK 65 pharmacokinetic properties 64 Immunogenicity 64 pharmacokinetic PK 64 immunogenic 64 safety tolerability pharmacokinetic 64 tolerability profile 63 pharmacodynamic PD 63 highly immunogenic 63 pharmacokinetic profiles 63 H#N# VLP vaccine 62 safety tolerability 62 biodistribution 62 Valortim R 62 Multimeric 61 inactivated influenza vaccine 61 pharmacodynamic properties 61 CYT# 61 pharmacodynamic 61 antitumor activity 61 Azedra 61 Menveo 61 preclinical efficacy 60 Phase Ib 60 oral bioavailability 60 Phase Ib clinical 60 mcg dose 60 pharmacokinetic characteristics 60 PRTX 60 antibody titers 60 safety tolerability pharmacokinetics 60 HspE7 59 pharmacokinetic PK profile 59 torezolid phosphate 59 preclinical studies 59 RDEA# 59 immunological 59 vivo efficacy 59 Phase Ia 59 VLP vaccine 59 antiviral potency 59 teriflunomide 59 pharmacodynamic profile 59 Phase Ib study 59 pharmacokinetic parameters 59 LC#m# 59 dose escalation trial 59 favorable pharmacokinetic profile 59 tolerability profiles 59 dose escalation study 58 immunological responses 58 ORMD 58 4CMenB 58 INCB# [001] 58 TG# [001] 58 seroprotection 58 Phase 1b clinical 58 tanespimycin 58 NEUGENE antisense 58 efficacy tolerability 58 Sym# 58 CCX# 58 pharmacokinetic studies 58 Vacc 4x 58 bioavailability 58 pharmacokinetic pharmacodynamic 58 pharmacodynamics PD 58 quadrivalent HPV vaccine 58 rHuPH# 58 tolerated dose MTD 58 live attenuated influenza 58 GAMMAGARD 58 Phase IIa clinical 58 pharmacokinetics pharmacodynamics 58 viral kinetics 58 Engerix B 57 tetravalent vaccine 57 cytotoxicity 57 hemagglutination inhibition HAI 57 Phase 1b trial 57 Phase IIa trial 57 dose cohorts 57 seroconversion 57 RiVax 57 neutralizing antibodies 57 Phase Ib II 57 preclinical 57 titers 57 Vaxfectin 57 Phase 1a clinical 57 VLPs 57 Valortim ® 57 VAX# 57 Altastaph 57 RE SURGE 57 ENMD # 57 BioVant 57 analgesic efficacy 57 PCV# 57 Pharmacokinetics PK 57 Heplisav 57 Phase 2a trial 57 PK PD 57 Pharmacokinetic 57 Phase 1a 57 pharmacodynamic effects 57 investigational hepatitis B 57 GLYX 57 dosing regimens 57 rFIXFc 57 DermaVir Patch 57 trivalent influenza vaccine 57 multiple ascending dose 57 vivo potency 57 ganetespib 57 peripheral blood mononuclear 57 Valortim 56 live attenuated vaccines 56 posaconazole 56 Universal Flu Vaccine 56 hemagglutination inhibition 56 GRN#L 56 thymalfasin 56 plasma pharmacokinetics 56 ascending doses 56 MGCD# [002] 56 bavituximab 56 VIR# 56 Pharmacokinetic PK 56 MenACWY CRM 56 LEP ETU 56 pandemic influenza vaccine 56 Androxal TM 56 AEG# 56 bioequivalence 56 valent pneumococcal conjugate vaccine 56 Phase 2b trial 56 MF# adjuvanted 56 conjugate vaccine 56 MAP# 56 vaccine TIV 56 TransVax TM 56 MF# adjuvanted vaccine 56 replicon 56 CEQ# 56 IMVAMUNE TM 56 JVRS 56 tolerability pharmacokinetics 56 PREFLUCEL 56 Phase 1b 56 GRNVAC1 56 antitumor efficacy 56 PEG Interferon lambda 56 neutralizing antibody 56 effector function 56 anti leukemic 56 dose limiting toxicities 56 NEUMUNE 56 Vaxfectin R 56 preclinically 56 pomalidomide 56 telbivudine 56 R#/MEM # 56 cannabinor 56 Japanese Encephalitis vaccine 56 vivo toxicology 56 retapamulin 56 ISIS # 56 viral kinetic 56 Cloretazine R VNP#M 56 serum antibody 56 ataluren 55 orally bioavailable 55 XmAb# 55 nanoviricides 55 clinical trial 55 antigenicity 55 trivalent inactivated influenza 55 tgAAC# 55 HI titers 55 HEPLISAV 55 solithromycin 55 Alocrest 55 dose cohort 55 dose regimen 55 systemic absorption 55 attenuated strain 55 decitabine 55 IMGN# 55 Phase #/#a 55 interferon beta 55 SparVax TM 55 Intercell vaccine 55 Vaxfectin ® 55 Phase 2a clinical 55 IIa clinical 55 pharmacodynamic profiles 55 Antiviral Activity 55 immunologic 55 maximally tolerated dose 55 phase IIa clinical 55 influenza VLP vaccine 55 CR# vcMMAE 55 UPLYSO 55 Vidofludimus 55 phase Ib 55 Tolerability 55 transgene expression 55 genotoxicity 55 pharmacokinetic PK study 55 GM CSF 55 antibody 55 milatuzumab 55 systemically administered 55 genotypic 55 Imvamune R 55 CERVARIX 55 pharmacokinetic equivalence 55 rNAPc2 55 Numax 55 Tarvacin TM 55 recombinant vaccine 55 TRIOLEX 55 APTIVUS 55 teduglutide 55 Interferon alpha 55 trivalent seasonal influenza 55 inhibitor RG# 55 #beta estradiol 55 mertansine 55 TOLAMBA 55 MenACWY 55 GFT# 55 GelVac TM 55 HGS ETR1 54 ZOSTAVAX 54 REP# 54 Ad5 54 NEUGENE 54 CELVAPAN H#N# 54 vivo 54 GLP toxicology studies 54 indibulin 54 Twinrix 54 SynCon TM DNA 54 Aurexis 54 PROSTVAC TM 54 virologic 54 Human cl 54 TPI ASM8 54 vidofludimus 54 phase IIb clinical 54 XOMA 3AB 54 oral prodrug 54 pharmacodynamic markers 54 tipranavir 54 JAK inhibitor 54 HGS ETR2 54 riociguat 54 DXL# 54 bicifadine 54 sapacitabine 54 dose escalation clinical 54 Triolex 54 SynCon ™ DNA 54 elacytarabine 54 nanoviricide drug 54 HQK 54 S/GSK# 54 CANCIDAS 54 phase 2a 54 non nucleoside 54 PRT# 54 bevirimat 54 radezolid 54 lintuzumab 54 IRX 2 54 single ascending dose 54 Traficet EN 54 PXD# 54 pharmacodynamic parameters 54 antibody titer 54 seasonal influenza vaccine 54 cobiprostone 54 efficacy endpoints 54 trivalent vaccine 54 GARDASIL ® 54 Factor VIIa 54 M2e 54 pDNA vaccines 54 peptide antigens 54 rBChE 54 Phase IIIb clinical 54 GeoVax vaccine 54 Marqibo 54 IMC A# 54 IDX# 54 Dasatinib 54 masitinib 54 Cloretazine 54 delafloxacin 54 vaccine LAIV 54 orally dosed 54 anticancer activity 54 optimal dosing regimen 54 virologic response 54 PSN# [002] 54 palivizumab 54 potent antiviral 54 PEGylated interferon beta 1a 54 nucleotide analog 54 davunetide intranasal AL 54 Protexia R 54 voreloxin 54 NP2 Enkephalin 54 Zysolin TM 54 Phase 2b study 54 nonclinical studies 54 phase IIb 54 vicriviroc 54 huC# DM4 54 Chemophase 54 HPV-#/# 54 hENT1 54 MVA#A 54 subcutaneously administered 54 ascending dose 54 OncoVEX GM CSF 54 depsipeptide 54 Imprime PGG 54 pafuramidine 54 ACAM FLU 54 adjuvanted 54 Elacytarabine 54 rPA anthrax vaccine 54 DAVANAT 54 ZFP Therapeutic 54 plasma concentrations 54 engraftment 54 Archexin 54 eltrombopag 54 phase IIa 54 ATL/TV# 54 adecatumumab 54 INT# [002] 54 polymerase inhibitor 53 Phenoptin 53 dose ritonavir 53 subcutaneous formulation 53 murine 53 IFN alpha 53 pandemic influenza vaccines 53 AACR NCI EORTC 53 poorly immunogenic 53 virological response 53 tumorigenicity 53 LT NS# 53 granulocyte colony stimulating 53 dose proportionality 53 neutralizing antibody responses 53 Non inferiority 53 Azixa 53 Virulizin ® 53 Novartis MenB vaccine 53 Menactra vaccine 53 galiximab 53 ProLindac 53 DASISION 53 elvitegravir 53 systemic toxicity 53 CBLC# 53 trastuzumab emtansine T DM1 53 Phase IIa 53 hGH CTP 53 viral load 53 CD8 responses 53 oral FTY# 53 PS# [001] 53 plasmid DNA vaccine 53 AZX# 53 DNA plasmids 53 celgosivir 53 LAIV 53 ROTATEQ 53 Phase III clinical 53 diabetic neuropathic pain 53 FTY# 53 Dacogen injection 53 nitazoxanide 53 HBsAg 53 ChimeriVax JE 53 randomized multicenter Phase III 53 Prodarsan ® 53 KINRIX 53 pneumococcal serotypes 53 RG# [001] 53 binding affinity 53 PF # [001] 53 sipuleucel T 53 viral suppression 53 active comparator 53 Phase 2b clinical 53 SCH # 53 EV# vaccine 53 BAL# [002] 53 TELCYTA 53 elotuzumab 53 humoral responses 53 mAbs 53 immune modulatory 53 active moiety 53 pertuzumab 53 obatoclax 53 optimal dosing 53 PEG PAL 53 plasmid DNA 53 eculizumab 53 secondary efficacy endpoints 53 antiangiogenic activity 53 antisense drug 53 simian immunodeficiency virus 53 Blinatumomab 53 serologic 53 favorable tolerability 53 Pegasys ® 53 pharmacodynamic endpoints 53 Efficacy 53 lucinactant 53 Cloretazine ® 53 tumor specific antigen 53 TMC# [002] 53 prucalopride 53 BAL# [001] 53 CRLX# 53 renal toxicity 53 Carfilzomib 53 varespladib 53 Havrix 53 MoxDuo ® IR 53 CaPre TM 53 PEGylated 53 titer 53 anti EGFR antibody 53 H#N# antigen 53 Apoptone 53 Amigal 53 Ostarine 53 SILENOR TM 53 Phase #b/#a 53 seasonal influenza vaccines 53 AAV vectors 53 CAIV T 53 Humenza 53 Cethromycin 53 ALN TTR# 53 ALN RSV# 53 Phase 2a 53 Anthim 53 Phase IIB 53 Onconase 53 Fluzone Intradermal vaccine 53 administered subcutaneously 53 antitumor 53 FluCide 53 fumagillin nanoparticles 53 receptor inhibitor 53 azacitidine 53 DermaVir 53 eliglustat tartrate 52 inactivated vaccine 52 OncoVEX 52 HCV polymerase inhibitor 52 severe rotavirus gastroenteritis 52 lentiviral 52 IMA# 52 AzaSite Plus 52 ritonavir boosted 52 GeoVax HIV AIDS 52 BrachySil 52 CTAP# Capsules 52 DAS# [001] 52 cynomolgus monkeys 52 PEG SN# 52 CLORETAZINE TM VNP#M 52 EFAPROXYN 52 mapatumumab 52 Phase IIb 52 CMV disease 52 clinical trials 52 Civacir 52 Tβ4 52 Sanaria vaccine 52 amrubicin 52 Nanobody 52 IFN gamma 52 Xanafide 52 Telbivudine 52 IMP# 52 virus AAV 52 Thiovir 52 Vaxfectin R adjuvant 52 placebo controlled 52 fluvastatin 52 p# biomarkers 52 novel VDA molecule 52 CoFactor 52 CCR5 mAb 52 forodesine 52 Symadex 52 NXL# 52 dose escalation 52 VLP vaccines 52 postexposure 52 bovine thrombin 52 IFN Beta 52 adjuvanted vaccines 52 DepoVax 52 therapeutic efficacy 52 PCV7 vaccine 52 IMVAMUNE R 52 pharmacokinetic interactions 52 GHRH 52 Toxoid 52 rPA 52 synthetic peptide 52 monovalent 52 Afatinib 52 Factor IX 52 ImmuKnow 52 lomitapide 52 OMP #M# 52 Debio 52 Radezolid 52 HEPLISAV ™ 52 TransVax ™ 52 TKM ApoB 52 H#N# influenza vaccine 52 coadministration 52 protease inhibitor 52 PREVENAR 52 Plicera 52 randomized Phase III 52 HIV RNA 52 Kahalalide F 52 Fx #A 52 Golimumab 52 CDK inhibitor 52 Fodosine 52 INGN 52 antitumor effects 52 cefepime 52 darunavir 52 serotype 52 TLR9 agonist 52 PCV1 52 clinical pharmacology studies 52 serogroup B 52 oral rivaroxaban 52 ritonavir boosting 52 REMUNE R 52 multicentre randomized 52 TMC# [001] 52 clinical endpoints 52 oritavancin 52 NGX# 52 antibody reagents 52 adjuvant 52 SRT# [003] 52 picoplatin 52 imetelstat 52 CBLB# 52 CYC# 52 protease inhibitor PI 52 ganaxolone 52 syngeneic 52 crofelemer 52 nonvaccine serotypes 52 MVA BN R 52 FOLOTYN ® 52 ancrod 52 neuraminidase inhibitor 52 Exelixis compounds 52 ChronVac C R 52 capsular polysaccharide 52 DR Cysteamine 52 low dose ritonavir 52 canakinumab 52 Excellarate 52 CIMZIA TM 52 Preclinical studies 52 PCV7 52 micafungin 52 #mg dose [001] 52 RH1 52 A3 adenosine receptor 52 placebo controlled Phase 52 LY# [003] 52 fosbretabulin 52 Pivotal Phase III 52 viremia 52 vaginal microbicide 52 MGd 52 VNP#M 52 EGFR antibodies 52 AVADO 52 Hiberix 52 investigational monoclonal antibody 52 Amrubicin 52 confirmatory clinical 52 ACTEMRA 52 alemtuzumab MS 52 Cloretazine R 52 menadione 52 Cethrin R 52 PMX # 52 prospectively defined 52 CD# upregulation 52 Locteron 52 Dalbavancin 52 VZV 52 7 valent pneumococcal 52 Sanofi Pasteur Fluzone 52 humanized anti 52 PLX PAD 52 #th Annual Interscience 52 Pharmacokinetics 52 AdVac ® 52 lopinavir 52 GelSite R polymer 52 RAV# 52 poliovirus vaccine 52 microgram doses 52 ADAGIO study 52 REG2 52 DPP4 52 Preclinical studies suggest 52 ELACYT 52 immunomodulators 52 AVN# [001] 52 investigational protease inhibitor 52 ongoing Phase 1b 52 NNRTI resistant virus 52 HIV HCV coinfected 52 dirucotide 52 protease inhibitors PIs 52 MVA BN 52 CTCE 52 aluminum hydroxide adjuvant 52 polysaccharide vaccines 52 Azedra TM 52 calcitonin 52 Radilex 51 ANA# 51 MBP# [001] 51 IgG1 51 mg kg BID 51 ZFN modified 51 huN# DM1 51 ORENCIA R 51 μg dose 51 ruxolitinib 51 adjuvanted H#N# 51 dosage regimens 51 antisense compounds 51 RSD# oral 51 EDEMA3 51 conserved antigens NP 51 preclinical toxicology 51 combinability 51 Vaxfectin TM 51 effector functions 51 MORAb 51 PSMA ADC 51 OXi# 51 Prostate AdenoCarcinoma Treatment 51 CG# [003] 51 tigecycline 51 #ME# 51 VA# [002] 51 PI3K inhibitor 51 ALN TTR 51 CTA# Injection 51 mGluR5 NAM 51 seliciclib 51 multicenter Phase II 51 BRIM3 51 ISTODAX 51 Chrysalin 51 randomized multicenter trial 51 encapsulates siRNAs 51 ZADAXIN 51 serum LDL cholesterol 51 oral gallium 51 ROTARIX 51 CMV infection 51 SNALP technology 51 potent antitumor activity 51 vitro cytotoxicity 51 CCR9 51 oral antiviral 51 Ixiaro 51 TAXUS Stent 51 Alpharadin 51 HuMax CD4 51 Viramidine 51 dose regimens 51 otelixizumab 51 LCP Tacro 51 rALLy clinical trial 51 PEGPH# 51 dosing 51 H#N# influenza vaccines 51 BCG vaccinated 51 INVIRASE 51 recombinant protein 51 sulodexide 51 neurotoxicity 51 YONDELIS 51 induces antibodies 51 Phase IIb clinical 51 atacicept 51 CTA# 51 RotaTeq 51 erythropoietic 51 subcutaneous PRO 51 oral diclofenac 51 H#N# pandemic influenza 51 apremilast 51 Prochymal 51 insulin detemir 51 generation antisense 51 Pentacel R 51 liprotamase 51 Oral NKTR 51 Anticalins ® 51 Omacetaxine 51 dacarbazine chemotherapy 51 NOX E# 51 perifosine 51 humanized antibodies 51 antigen 51 HuMax CD# 51 Dapagliflozin 51 Japanese Encephalitis Vaccine 51 Tezampanel 51 Oritavancin 51 double blind placebo 51 SynCon 51 transfected 51 PROCHYMAL 51 EOquin 51 investigational drug 51 KRN# 51 Nanobody ® 51 humoral immune responses 51 inactivated vaccines 51 APOPTONE 51 Prevenar 51 Anticalins 51 BLA submission 51 clofarabine 51 Onrigin TM 51 CD8 T cell 51 MAGE A3 ASCI 51 influenza vaccines 51 TACI Ig 51 biodistribution studies 51 saquinavir 51 hepatitis B immunoglobulin 51 ocular formulation 51 selective modulator 51 parathyroid hormone PTH 51 antitumor effect 51 Natalizumab 51 pitavastatin 51 antimicrobial efficacy 51 humoral immunity 51 MAGE A3 51 Rasilez Tekturna 51 Toxicities 51 Virulizin R 51 alvespimycin 51 immunostimulatory 51 Vaxfectin TM adjuvant 51 Vaxfectin TM formulated 51 ZYBRESTAT fosbretabulin 51 Anticalins R 51 Adjuvanted 51 Exherin TM 51 LCP AtorFen 51 pandemic influenza strains 51 bioactivity 51 Dynavax HBV vaccine 51 NexACT 51 EZN 51 daptomycin 51 Ophena 51 Protectan CBLB# 51 MAXY G# 51 COMFORT II 51 Q#IR 51 DB# [003] 51 HGS# 51 clinically relevant 51 Fidaxomicin 51 intravenous dosing 51 PREOS 51 cGMP manufacture 51 LUX Lung 51 multicenter randomized placebo controlled 51 vitro experiments 51 interferon IFN 51 EpCAM 51 HIF PHI 51 adenoviral 51 Pralatrexate 51 RoACTEMRA 51 favorable pharmacokinetic 51 Quadrivalent 51 monotherapy 51 vitro studies 51 trodusquemine 51 multivalent vaccine 51 EXPAREL ™ 51 MLN# 51 Omacetaxine mepesuccinate 51 lymphocyte counts 51 blinded randomized 51 GAP #B# 51 antibody titres 51 RE LY ® 51 SCIg 51 adenovirus vector 51 bosentan 51 MoxDuo IR 51 Acetavance 51 MEK inhibitor 51 Immune responses 51 Proxinium TM 51 neuroprotective properties 51 SPIRIT III 51 C1 INH 51 transfected cells 51 PBMCs 51 ALISTA 51 GRNCM1 51 HCV infected 51 dose escalation Phase 51 non adjuvanted vaccines 51 BiTE antibodies 51 Eg5 51 Bezielle 51 herpes zoster vaccine 51 ILLUMINATE 51 glufosfamide 51 USL# 51 Topical Interferon Alpha 2b 51 HuMax EGFr 51 liposomal formulation 51 factor G CSF 51 ceftazidime 51 MEK inhibitors 51 NO# [002] 51 alfa 2a 51 follistatin 51 INTELENCE 51 BeneFIX 51 dose intramuscular 51 LHRH antagonists 51 Phase #/#a clinical 51 fosamprenavir 51 TLR7 51 intramuscular 51 oral deforolimus 51 interleukin IL -# 51 Spiegelmer ® 51 TYZEKA 51 Virological 51 OvaRex R 51 CD4 + cell 51 tezampanel 51 TLR agonists 51 bactericidal activity 51 ZYBRESTAT 51 CMV vaccine 50 immunomodulator 50 blinatumomab 50 hemostatic efficacy 50 ALTU 50 Allovectin 7 R 50 PRE SURGE 50 Initiated Phase 50 urocortin 2 50 inecalcitol 50 melphalan prednisone 50 INCB# [003] 50 Clolar 50 Panzem R 50 trials RCTs 50 Triapine R 50 subunit vaccine 50 Belerofon 50 rapid virologic response 50 evaluable subjects 50 IFN α 50 PROMACTA 50 Reolysin 50 MUC1 50 trastuzumab DM1 T DM1 50 romiplostim 50 Modified Vaccinia Ankara MVA 50 Darinaparsin 50 placebo controlled Phase III 50 interferon lambda 50 EDEMA3 trial 50 dissolving microneedles 50 bivalent vaccine 50 fidaxomicin Phase 3 50 albinterferon alfa 2b 50 lentiviral vector 50 dosing frequency 50 noninferiority 50 nucleoside 50 mRCC 50 TBC# 50 adalimumab 50 Phase IIb trials 50 ORENCIA ® 50 randomized Phase 2b 50 HBV vaccine 50 TYGACIL 50 nucleoside naive patients 50 MyVax R 50 kinase inhibition 50 Neugene 50 COPEGUS 50 nephrotoxicity 50 Tovaxin 50 rotavirus vaccine 50 PEGylated anti 50 vorinostat 50 Anticalin R 50 TB4 50 PLX cells 50 DPX Survivac 50 SAR# [004] 50 Luteinizing Hormone Releasing Hormone 50 isatoribine 50 LEVAQUIN ® 50 HIF PH inhibitors 50 conjugate vaccines 50 Phase 1b clinical trials 50 adefovir 50 Forodesine HCl 50 MF# adjuvant 50 Novavax VLP vaccine 50 myelodysplastic syndromes MDS 50 lisdexamfetamine dimesylate 50 intravascular hemolysis 50 subcutaneous injections 50 TAXUS VI 50 BNC# 50 wilate ® 50 sustained virologic response 50 MGCD# [001] 50 Tamibarotene 50 Tyrima 50 Adalimumab 50 TRANSFORMS 50 QLT# 50 PI3K delta 50 rALLy trial 50 antibodies 50 bazedoxifene conjugated estrogens 50 limiting toxicity DLT 50 nasal spray influenza 50 hyperphenylalaninemia HPA due 50 EOquin TM 50 antidepressant efficacy 50 monoclonal 50 G CSF 50 BiTE R 50 Campath alemtuzumab 50 pan HDAC inhibitor 50 neratinib 50 eculizumab therapy 50 Vaccine Diphtheria CRM# Protein 50 MVA nef